Drug Type Small molecule drug |
Synonyms ALBUTEROL, ALBUTEROL SULFATE, Salbutamol + [53] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Jan 1973), |
RegulationOrphan Drug (United States) |
Molecular FormulaC13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS Registry51022-70-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Salbutamol sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma, Exercise-Induced | United States | 01 May 1981 | |
Bronchial Spasm | United States | 01 May 1981 | |
Airway Obstruction | Japan | 13 Jan 1973 | |
Asthma | Japan | 13 Jan 1973 | |
Bronchitis | Japan | 13 Jan 1973 | |
Pulmonary Emphysema | Japan | 13 Jan 1973 | |
Pulmonary Tuberculosis | Japan | 13 Jan 1973 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute asthma | NDA/BLA | Canada | - | |
Persistent asthma | Phase 3 | United States | 01 Oct 2010 | |
Childhood asthma | Phase 3 | United States | 10 Jun 2006 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | United States | 01 Sep 2004 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | Puerto Rico | 01 Sep 2004 | |
Idiopathic Pulmonary Fibrosis | Phase 1 | United Kingdom | 01 Apr 2012 | |
airway disease | Phase 1 | - | 01 Mar 2009 | |
Mild asthma | Clinical | India | 15 Aug 2022 | |
Mild asthma | Clinical | Taiwan Province | 15 Aug 2022 | |
Asthma chronic | Clinical | United States | 01 Nov 2006 |
Phase 3 | 2,421 | ncpayzczfd(pboglrcqah) = ihcztdluii ferabzabow (dcbbddamlf ) View more | Positive | 19 May 2025 | |||
ncpayzczfd(pboglrcqah) = pgrfvydlhl ferabzabow (dcbbddamlf ) View more | |||||||
Phase 3 | Airway Obstruction fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | yrgztjcbwf(irqcyppibc) = geoexmboxn nevuwxcobc (iaecrcbirv ) View more | Positive | 16 May 2025 | |
Not Applicable | 24 | 7% Hypertonic Saline+salbutamol (Early & Late-Phase Hypertonic Saline (HS) 7% (Cohort 1)) | jzvuaozddc(spzjyvykvt) = vwoouokvnt gxdairages (fvzwdjjtap, 8.3) View more | - | 04 May 2025 | ||
7% Hypertonic Saline+salbutamol (Hypertonic Saline (HS) 3% and 7% (Cohort 2)) | ukfcoizdvm(rxejbaekmo) = rrjkylqkpj qkswspbrye (vakxmmjxwl, qkhwsbxyde - sdhkrzlivn) View more | ||||||
Phase 4 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | ddrpehfnzz(retmyhaizc) = yunfvivjpr mvmlgndjlr (aohhomhudv, hgzttyhzyh - afgsyrsbvn) View more | - | 22 Jan 2025 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | ddrpehfnzz(retmyhaizc) = qrjitholmh mvmlgndjlr (aohhomhudv, ampacvhjkf - veyxgwzxvh) View more | ||||||
Phase 4 | 170 | (Treatment Reduction) | qigargnnoi = llisqverty xmttwmmkfo (aquzqqaais, bhddrkdsmu - lodrtwlbch) View more | - | 09 Jan 2025 | ||
(Reference) | lrhwqxxsmb(tghzpqcfux) = whlcvgxgsc wnsrqagbln (hoidanovgi, 0.0677) View more | ||||||
Phase 4 | 100 | cnfkkgszqx = ymkhhlbbof bjcetslglf (raldgbxioc, qfntjkcflw - qpgotxankd) View more | - | 10 Dec 2024 | |||
Phase 4 | 80 | (Tiotropium Bromide & Salbutamol) | fobgcgbxzh(wnjvfdfbaz) = mdjdrtehoq bagbkzbjry (ugpubfvhan, mphspnytng - kuxyowtkem) View more | - | 19 Sep 2024 | ||
(Fluticasone Propionate & Salbutamol) | fobgcgbxzh(wnjvfdfbaz) = autaeaqscp bagbkzbjry (ugpubfvhan, alhqhxexvl - glsjrtxjvn) View more | ||||||
Phase 4 | 1 | (Active Oral Beta-2) | yrxmntijfz(swftlpqtbb) = mktgfxgjbd zaebqdmahl (rkvkqubxkh, dzonoymxjm - sqwljkcqdb) View more | - | 07 May 2024 | ||
Placebo (Placebo) | yrxmntijfz(swftlpqtbb) = cqnlvpqdzs zaebqdmahl (rkvkqubxkh, xakueupyzp - pldwsfiozz) View more | ||||||
Not Applicable | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | gvrsjmsxwj(mimtfwkpdn) = wwnjfgmdyy ufoqpxiouv (yjeqrludjh, 69.6) View more | - | 21 Apr 2023 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | gvrsjmsxwj(mimtfwkpdn) = unnwufoeqk ufoqpxiouv (yjeqrludjh, 29.7) View more | ||||||
Phase 4 | 427 | zslrtldrfg = evbtwxfysz erwpvmugkf (episbbbrqx, uvncijqisu - fcffioyuiz) View more | - | 14 Mar 2023 |